Antibody Development Segment has the Largest Share of Service in the Asia Pacific Custom Antibody Market during 2021–2028

According to a new market research study on “Asia Pacific Custom Antibody Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Service, Type, Source, Research Area, and End User,” is expected to reach US$ 174.8 million by 2028 from US$ 82.3 million in 2021. The market is estimated to grow at a CAGR of 11.4% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific custom antibody market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high demand in research, market consolidations strategies adopted by biotechnology companies, and production and development services offered by custom antibody providers are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the high cost of production.

Countries in the Asia Pacific are encountering challenges due to rising incidences of COVID-19. The COVID-19 pandemic has put a significant strain on the health systems of many countries around the world. Testing capacity in many Asia Pacific nations was limited and of low quality in the initial days of the pandemic, which led to a surge in the COVID-19 cases. However, many countries, such as South Korea, Japan, and Singapore, were efficiently contained the situation through robust tracking and testing. Also, India has the second-highest number of cases in the world after the US. Thus, COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective diagnostics and therapeutics for the treatment of COVID 19, have put the healthcare research industry in a critical situation in the Asia Pacific region. However, many market players now realized the importance of antibody testing for COVID 19, which is expected to raise demand for custom antibodies during the forecast period.

The market for custom antibody market is segmented into service, type, source, research area, and end user. Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, also the same segment is estimated to grow at a significant CAGR due to growing focus of researchers on high-quality custom antibodies for reproducibility during the forecast period.

Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck KGAA, Abcam, Genscript, Agilent Technologies, Inc., and Cell Signaling Technology, Inc. are among the leading companies in the Asia Pacific custom antibody market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2020, Thermo Fisher Scientific has entered into collaboration with WuXi Diagnostics and the Mayo Clinic to develop ELISA test for detection of IgM and IgG antibodies to the novel coronavirus.

The report segments the Asia Pacific Custom Antibody market as follows:

By Service

• Antibody Development
• Antibody Production and Purification
• Antibody Fragmentation and Labelling

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Custom Antibodies

By Source

• Mice
• Rabbits
• Others

By Research Area

• Oncology
• Immunology
• Stem Cells
• Infectious Diseases
• Neurobiology
• Cardiovascular Diseases
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific